$Palantir (PLTR.US)$ There is a lot of valuation space that can be compressed.

$iShares Semiconductor ETF (SOXX.US)$ The reason I am less bearish about Soxx as opposed to other sectors (e.g., XLF, XLI, XLC, IGV, XLY, XLP, AI-related utilities) is soxx’s return since 2024 has been modest. There is fair amount of recession fear and P/E compression in the share price.  The technical is still bad, but less risky from fundamental perspective.

$S&P 500 Index (.SPX.US)$ Peak AI and recession are scary concepts. Don’t assume the index’s correction is over at some point, but only trade in a short-term basis. Barring from major favorable news (e.g., tariff off, fed pivot), I feel some consolidation pattern has to be established before a durable bottom and an entry point for uptrend following.

$Broadcom (AVGO.US)$ I don’t believe the 60-90 billion servicable adressable market in 2027, with each customer accounting 20 billion on average (although they are engaging with another four customers). Things change, business plans may change. Google’s TPU will not be able to compete with Blackwell in performance, generality of workloads, ready-to-use, and innovation pace. Even for internal use, return on investment for asic chips is unlikely comparable to GPUs.

$Regeneron Pharmaceuticals (REGN.US)$ higher low?

$NVIDIA (NVDA.US)$ Comparatively speaking, I am less bearish about nvda than avgo and mrvl. Google and Amzn’s custom chips will not be able to compete with blackwell for cloud customers. Long term remains bullish about this company.

$Marvell Technology (MRVL.US)$ From August 2024 low to recent high, it almost tripled. There is no way the company’s fundamentals could change so much. It’s the momentum trade. The hedge funds all use time-series analysis to pump and dump. Don’t try to rationalize why it went up so much.

$Marvell Technology (MRVL.US)$ Another broken chart. Very hurtful to the bulls.

$Agilent Technologies (A.US)$ Recovery, normalization, return to growth, moaty etc, no matter how you slice and dice and twist the narrative, the fact is medical research and device companies do not have meaningful growth, but their China sales face meaningful risks.

$Advanced Micro Devices (AMD.US)$ Might be the beginning of something.